Department of Emergency Medicine, Brooke Army Medical Center, 3841 Roger Brooke Dr, Fort Sam Houston, TX, 78234, USA.
Assistant Professor, Department of Pharmacy Practice, Marshall B. Ketchum University College of Pharmacy, Fullerton, CA, USA.
Intern Emerg Med. 2021 Nov;16(8):2231-2241. doi: 10.1007/s11739-021-02749-1. Epub 2021 May 6.
Antimicrobial resistance is a growing threat to public health and an increasingly common problem for acute care physicians to confront. Several novel antibiotics have been approved in the past decade to combat these infections; however, physicians may be unfamiliar with how to appropriately utilize them. The purpose of this review is to evaluate novel antibiotics active against resistant gram-negative bacteria and highlight clinical information regarding their use in the acute care setting. This review focuses on novel antibiotics useful in the treatment of infections caused by resistant gram-negative organisms that may be seen in the acute care setting. These novel antibiotics include ceftolozane/tazobactam, ceftazidime/avibactam, meropenem/vaborbactam, imipenem/cilistatin/relebactam, cefiderocol, plazomicin, eravacycline, and omadacycline. Acute care physicians should be familiar with these novel antibiotics so they can utilize them appropriately.
抗菌药物耐药性是对公众健康的日益严重的威胁，也是急性护理医生越来越常见的需要面对的问题。在过去十年中，已经批准了几种新型抗生素来对抗这些感染；然而，医生可能不熟悉如何正确使用它们。本综述的目的是评估针对耐药革兰氏阴性菌的新型抗生素，并强调其在急性护理环境中使用的临床信息。本综述重点介绍了在急性护理环境中治疗耐药革兰氏阴性菌引起的感染有用的新型抗生素。这些新型抗生素包括头孢洛扎/他唑巴坦、头孢他啶/阿维巴坦、美罗培南/瓦博巴坦、亚胺培南/西司他丁/雷利巴坦、头孢地尔、硫酸帕拉米韦、依拉环素和奥马环素。急性护理医生应该熟悉这些新型抗生素，以便能够正确使用它们。
